Results 291 to 300 of about 1,250,673 (409)

Body Biofluids for Minimally‐Invasive Diagnostics: Insights, Challenges, Emerging Technologies, and Clinical Potential

open access: yesAdvanced Healthcare Materials, EarlyView.
Recent advances in diagnostics have accelerated the development of miniaturized wearable technologies for the continuous monitoring of diseases. This paradigm is shifting healthcare away from invasive, centralized blood tests toward decentralized monitoring, using alternative body biofluids.
Lanka Tata Rao   +2 more
wiley   +1 more source

Personalizing Treatment for Pancreatic Ductal Adenocarcinoma: The Emerging Role of Minimal Residual Disease in Perioperative Decision-Making. [PDF]

open access: yesCancers (Basel)
Theocharopoulos C   +7 more
europepmc   +1 more source

Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer.

open access: yesNew England Journal of Medicine, 2003
C. Ribic   +12 more
semanticscholar   +1 more source

Microphysiological Systems of Lymphatics and Immune Organs

open access: yesAdvanced Healthcare Materials, EarlyView.
This review surveys recent progress in engineering lymphatic microenvironments and immune organoids within microphysiological systems, emphasizing innovative strategies to recreate the biochemical and biophysical complexity of native lymphatic tissues.
Ishita Jain   +2 more
wiley   +1 more source

Optimizing Workflow for OncotypeDX Result Turnaround Time at a Safety Net Hospital. [PDF]

open access: yesGlob J Qual Saf Healthc
Wu J   +7 more
europepmc   +1 more source

The Effect of Intrathecal Dexmedetomidine as an Adjuvant to Spinal Anesthesia: Double Blind Study

open access: hybrid, 2016
Shah Bipin K.   +6 more
openalex   +1 more source

Antimicrobial Efficacy of a Taurolidine‐Based Antimicrobial Compound on Contaminated Surfaces Simulated in a Standardized 4‐Field Test

open access: yesAdvanced Healthcare Materials, EarlyView.
As implantable medical devices become indispensable to modern medicine, a silent threat grows alongside them: device‐associated infections. Despite decades of antibiotic innovation, infection rates keep climbing, costing lives and billions in healthcare expenses.
Benito Baldauf   +5 more
wiley   +1 more source

Clinical stage II non-small cell lung cancer: can we "just give adjuvant therapy"? [PDF]

open access: yesJ Thorac Dis
Jindani R   +9 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy